by secretome | Oct 28, 2024 | Investors, News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the allowance of a composition of matter patent for its lead asset, STM-01, a novel nCPC...
by secretome | Sep 17, 2024 | Investors, News
Dallas-based venture capital family office HEST Investments announced its successful Special Purpose Vehicle (SPV) of a $1.8 million investment in Baltimore-based Secretome Therapeutics, which has a presence at BioLabs at Pegasus Park in Dallas. HEST said the...
by secretome | Jul 18, 2024 | Journals, News
DALLAS–(BUSINESS WIRE)–Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “Margot’s unparalleled...
by secretome | Sep 20, 2023 | Investors, News
12 outstanding scientists hailing from Maryland-based research institutions and companies have been selected as recipients of these prestigious grants. Among the distinguished awardees are researchers from esteemed academic institutions, such as Johns Hopkins...
by secretome | Jul 18, 2023 | Investors, News
DALLAS, TX, July 18, 2023 — Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “I have been fortunate to be part...
by secretome | Jun 26, 2023 | Investors, News
DALLAS, TX, June 26, 2023 — Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors. “I have been fortunate to be...
